Prostate Cancer
Prostate Cancer
Advertisement
Emily MenendezSUO 2023 | November 29, 2023
Single-port and multi-port RARP approaches were found to provide similar 1-year biochemical recurrence rates.
Read More
Katy MarshallSUO 2023 | November 28, 2023
The generative AI model ChatGPT was fed a prostate cancer risk stratification algorithm.
Katy MarshallSUO 2023 | November 27, 2023
The primary outcome was the potential for focal or hemi-gland ablation following analysis of the final pathologic specimen.
Zachary BessetteSUO 2023 | November 22, 2023
New research sheds light on the safety of (177Lu)–PSMA-617 for patients with mCRPC and poor bone marrow reserve.
Ravi A. Madan, MDCRPC | November 22, 2023
Dr. Madan describes the background for the PARPi approvals stemming from recent studies and the ongoing issues with them.
Zachary BessetteSUO 2023 | November 21, 2023
A poster reported on AEs occurring after Lu-PSMA treatment, as well as variables associated with ER visits.
Emily MenendezCRPC | November 17, 2023
Compared with ADT alone, apalutamide plus ADT had a favorable hazard ratio across all end points regardless of age.
Emily MenendezProstate Cancer | November 17, 2023
There was a 57% increase in the number of non-European prostate cancer cases compared to previous association studies.
Zachary BessetteLocalized | November 17, 2023
The FDA approved enzalutamide as the first AR-signaling inhibitor for the treatment of nmCSPC with high-risk BCR.
Michael Morris, MDRoundtable | November 16, 2023
The panel shares insights on future advancements in the field.
Michael Morris, MDRoundtable | November 16, 2023
The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023.
Michael Morris, MDRoundtable | November 16, 2023
The panel discusses treatment-related adverse events, including hematologic toxicities, xerostomia, and more.
Michael Morris, MDRoundtable | November 16, 2023
The panel discuss patient interest in receiving radioligand therapy in the context of cost and access challenges.
Michael Morris, MDRoundtable | November 16, 2023
The panel discusses results of the phase 3 PSMAfore study presented at ESMO 2023.
Michael Morris, MDRoundtable | November 16, 2023
The panel talks "pearls of wisdom" with radioligand therapy.
Michael Morris, MDRoundtable | November 16, 2023
The panel discusses recommended frequency of scans for patients receiving radioligand therapy, PSA response, and more.
Michael Morris, MDRoundtable | November 13, 2023
The panel discussed initial access issues with radioligand therapy, as well as interdisciplinary team collaboration.
Emily MenendezRLT | November 10, 2023
A single priming dose of 177Lu-PSMA-617 followed by pembrolizumab maintenance was found to be a safe treatment for mCRPC.
Emily MenendezLocalized | November 10, 2023
PCSM was found to be lower after local therapy use in patients with higher-risk disease, particularly after RP.
Zachary BessetteAdvanced Imaging | November 7, 2023
Clarity announced that 50 patients have now been imaged with 64Cu-SAR-Bombesin in its US-based diagnostic trial.
Advertisement
Advertisement
Advertisement